Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: Business Wire
Study will treat 40 COVID-19 infected patients hospitalized with moderate-to-severe symptomsEfficacy endpoints include viral shedding and resolution of symptoms PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has received approval from the Institutional Review Board (IRB) at Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus (COVID-19) infected patients.On March 23, 2020, Can-Fite announced it submitted Piclidenoson for a COVID-19 compassionate use program to the IRB at Rabin Medical Center. Upon review, the IRB recommended that Can-Fite advance into a full clinical study. Can-Fite submitted the study protocol, which has been approved by the IRB. Patient enrollment and dosing wil
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd Sponsored ADR (Israel) news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite BioPharma Ltd. (NYSE: CANF) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NVAccesswire
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal [Yahoo! Finance]Yahoo! Finance
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalBusiness Wire
- Can-Fite BioPharma Ltd. (NYSE: CANF) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CANF
Sec Filings
- 4/25/24 - Form 6-K
- 4/15/24 - Form 6-K
- 4/10/24 - Form EFFECT
- CANF's page on the SEC website